All In Biotech

Drug Trial Radar · NCT00896532

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 419 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

419

Actual

Start

Jun 3, 2009

Primary completion

Feb 21, 2011

Study completion Feb 18, 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.

Conditions

  • Low Bone Mineral Density
  • Postmenopausal Osteoporosis

Interventions

  • Placebo to RomosozumabDrug

    Administered by subcutaneous injection QM or Q3M.

  • AlendronateDrug

    Administered orally once a week

  • TeriparatideDrug

    Teriparatide 20 μg administered by subcutaneous injection once a day

  • RomosozumabDrug

    Administered by subcutaneous injection

  • DenosumabDrug

    Denosumab 60 mg administered by subcutaneous injection Q6M

  • Placebo to DenosumabDrug

    Administered by subcutaneous injection Q6M

  • Zoledronic acidDrug

    Zoledronic acid 5 mg administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline at Month 12 in BMD at the Lumbar SpineTime frame: Baseline to 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.